List of Tlando drug patents
Tlando is owned by Antares Pharma Inc.
Tlando contains Testosterone Undecanoate.
Tlando has a total of 12 drug patents out of which 0 drug patents have expired.
Tlando was authorised for market use on 28 March, 2022.
Tlando is available in capsule;oral dosage forms.
Tlando can be used as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired)..
The generics of Tlando are possible to be released after 28 April, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304960 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US8865695 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US8778922 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US9949985 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11311555 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US10226473 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US9943527 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11433083 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11364249 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US10716794 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(14 years from now) | |
| US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: CAPSULE;ORAL
TLANDO family patents
55
United States
4
European Union
3
Australia
3
Japan
2
Canada
2
Mexico
2
China
2
Brazil
1
Taiwan, Province of China
1
Korea, Republic of
1
Israel
1
Uruguay
1
Russia
1
South Africa
1
Argentina
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic